Regulation of cellular miRNA expression by human papillomaviruses

Biochimica et Biophysica Acta - Gene Regulatory Mechanisms

Volumn 1809, Issue 11-12, 2011, Pages 668-677

  Zheng, Zhi Ming ^a   Wang, Xiaohong ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Cervical cancer; Gene expression; Human papillomaviruses; MicroRNAs; Oncogenes; Tumor suppressor genes

Indexed keywords

MICRORNA; MICRORNA 106B; MICRORNA 15; MICRORNA 16; MICRORNA 17; MICRORNA 21; MICRORNA 23B; MICRORNA 25; MICRORNA 34A; MICRORNA 92; MICRORNA 93; MYC PROTEIN; PROTEIN E6; PROTEIN E7; PROTEIN P53; RETINOBLASTOMA PROTEIN; TRANSCRIPTION FACTOR E2F; UNCLASSIFIED DRUG; VIRUS RNA;

CELL PROLIFERATION; DNA REPLICATION; GENE EXPRESSION REGULATION; HUMAN; LIFE CYCLE; MOLECULAR INTERACTION; NONHUMAN; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UTERINE CERVIX CANCER; VIRUS CARCINOGENESIS; VIRUS GENE; VIRUS REPLICATION; WART VIRUS;

BASE SEQUENCE; DNA REPLICATION; GENE EXPRESSION REGULATION, VIRAL; HUMAN PAPILLOMAVIRUS 16; HUMANS; MICRORNAS; MODELS, GENETIC; MOLECULAR SEQUENCE DATA; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; TUMOR SUPPRESSOR PROTEIN P53;

HUMAN PAPILLOMAVIRUS; PAPILLOMAVIRIDAE;

EID: 80655127810     PISSN: 18749399     EISSN: 18764320     Source Type: Journal    
DOI: 10.1016/j.bbagrm.2011.05.005     Document Type: Review

References (123)

1. Zheng Z.M., Baker C.C. Papillomavirus genome structure, expression, and post-transcriptional regulation. Front. Biosci. 2006, 11:2286-2302.
2. Scheffner M., Werness B.A., Huibregtse J.M., Levine A.J., Howley P.M. The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 1990, 63:1129-1136.
3. Dyson N., Howley P.M., Munger K., Harlow E. The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 1989, 243:934-937.
4. Gonzalez S.L., Stremlau M., He X., Basile J.R., Munger K. Degradation of the retinoblastoma tumor suppressor by the human papillomavirus type 16 E7 oncoprotein is important for functional inactivation and is separable from proteasomal degradation of E7. J. Virol. 2001, 75:7583-7591.
5. Lewis B.P., Burge C.B., Bartel D.P. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005, 120:15-20.
6. Grimson A., Farh K.K., Johnston W.K., Garrett-Engele P., Lim L.P., Bartel D.P. MicroRNA targeting specificity in mammals: determinants beyond seed pairing. Mol. Cell 2007, 27:91-105.
7. Selbach M., Schwanhausser B., Thierfelder N., Fang Z., Khanin R., Rajewsky N. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
8. Baek D., Villen J., Shin C., Camargo F.D., Gygi S.P., Bartel D.P. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
9. Cullen B.R. Viruses and microRNAs. Nat. Genet. 2006, 38(Suppl):S25-S30.
10. Farazi T.A., Spitzer J.I., Morozov P., Tuschl T. miRNAs in human cancer. J. Pathol. 2011, 223:102-115.
11. McMurray H.R., McCance D.J. Human papillomavirus type 16 E6 activates TERT gene transcription through induction of c-Myc and release of USF-mediated repression. J. Virol. 2003, 77:9852-9861.
12. Veldman T., Liu X., Yuan H., Schlegel R. Human papillomavirus E6 and Myc proteins associate in vivo and bind to and cooperatively activate the telomerase reverse transcriptase promoter. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:8211-8216.
13. Liu X., Dakic A., Chen R., Disbrow G.L., Zhang Y., Dai Y., Schlegel R. Cell-restricted immortalization by human papillomavirus correlates with telomerase activation and engagement of the hTERT promoter by Myc. J. Virol. 2008, 82:11568-11576.
14. Gewin L., Galloway D.A. E box-dependent activation of telomerase by human papillomavirus type 16 E6 does not require induction of c-myc. J. Virol. 2001, 75:7198-7201.
15. Oh S.T., Kyo S., Laimins L.A. Telomerase activation by human papillomavirus type 16 E6 protein: induction of human telomerase reverse transcriptase expression through Myc and GC-rich Sp1 binding sites. J. Virol. 2001, 75:5559-5566.
16. Al Moustafa A.E., Foulkes W.D., Benlimame N., Wong A., Yen L., Bergeron J., Batist G., Alpert L., Alaoui-Jamali M.A. E6/E7 proteins of HPV type 16 and ErbB-2 cooperate to induce neoplastic transformation of primary normal oral epithelial cells. Oncogene 2004, 23:350-358.
17. Wang Y.W., Chang H.S., Lin C.H., Yu W.C. HPV-18 E7 conjugates to c-Myc and mediates its transcriptional activity. Int. J. Biochem. Cell Biol. 2007, 39:402-412.
18. Blackwood E.M., Eisenman R.N. Max: a helix-loop-helix zipper protein that forms a sequence-specific DNA-binding complex with Myc. Science 1991, 251:1211-1217.
19. Zeller K.I., Zhao X., Lee C.W., Chiu K.P., Yao F., Yustein J.T., Ooi H.S., Orlov Y.L., Shahab A., Yong H.C., Fu Y., Weng Z., Kuznetsov V.A., Sung W.K., Ruan Y., Dang C.V., Wei C.L. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:17834-17839.
20. O'Donnell K.A., Wentzel E.A., Zeller K.I., Dang C.V., Mendell J.T. c-Myc-regulated microRNAs modulate E2F1 expression. Nature 2005, 435:839-843.
21. Chang T.C., Yu D., Lee Y.S., Wentzel E.A., Arking D.E., West K.M., Dang C.V., Thomas-Tikhonenko A., Mendell J.T. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat. Genet. 2008, 40:43-50.
22. Huibregtse J.M., Scheffner M., Howley P.M. Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with p53, and ubiquitination of associated proteins. Mol. Cell. Biol. 1993, 13:4918-4927.
23. Scheffner M., Huibregtse J.M., Vierstra R.D., Howley P.M. The HPV-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of p53. Cell 1993, 75:495-505.
24. Beno I., Rosenthal K., Levitine M., Shaulov L., Haran T.E. Sequence-dependent cooperative binding of p53 to DNA targets and its relationship to the structural properties of the DNA targets. Nucleic Acids Res. 2011, 39:1919-1932.
25. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
26. Brosh R., Shalgi R., Liran A., Landan G., Korotayev K., Nguyen G.H., Enerly E., Johnsen H., Buganim Y., Solomon H., Goldstein I., Madar S., Goldfinger N., Borresen-Dale A.L., Ginsberg D., Harris C.C., Pilpel Y., Oren M., Rotter V. p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol. Syst. Biol. 2008, 4:229.
27. Ou Y.H., Chung P.H., Hsu F.F., Sun T.P., Chang W.Y., Shieh S.Y. The candidate tumor suppressor BTG3 is a transcriptional target of p53 that inhibits E2F1. EMBO J. 2007, 26:3968-3980.
28. Tazawa H., Tsuchiya N., Izumiya M., Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:15472-15477.
29. Tao Y., Kassatly R.F., Cress W.D., Horowitz J.M. Subunit composition determines E2F DNA-binding site specificity. Mol. Cell. Biol. 1997, 17:6994-7007.
30. Bueno M.J., Gomez d.C., Laresgoiti U., Fernandez-Piqueras J., Zubiaga A.M., Malumbres M. Multiple E2F-induced microRNAs prevent replicative stress in response to mitogenic signaling. Mol. Cell. Biol. 2010, 30:2983-2995.
31. Woods K., Thomson J.M., Hammond S.M. Direct regulation of an oncogenic micro-RNA cluster by E2F transcription factors. J. Biol. Chem. 2007, 282:2130-2134.
32. Petrocca F., Visone R., Onelli M.R., Shah M.H., Nicoloso M.S., de M., Iliopoulos I.D., Pilozzi E., Liu C.G., Negrini M., Cavazzini L., Volinia S., Alder H., Ruco L.P., Baldassarre G., Croce C.M., Vecchione A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell 2008, 13:272-286.
33. Jemal A., Siegel R., Xu J., Ward E. Cancer statistics, 2010. CA Cancer J. Clin. 2010, 60:277-300.
34. Bernard H.U., Burk R.D., Chen Z., van Doorslaer K., Hausen H., de Villiers E.M. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010, 401:70-79.
35. Clifford G., Franceschi S., Diaz M., Munoz N., Villa L.L. Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 2006, 24(Suppl 3). S3-26-S3/34.
36. Parkin D.M., Bray F. Chapter 2: the burden of HPV-related cancers. Vaccine 2006, 24(Suppl 3). S3-11-S3/25.
37. Di Leva G., Croce C.M. Roles of small RNAs in tumor formation. Trends Mol. Med. 2010, 16:257-267.
38. Gregory P.A., Bert A.G., Paterson E.L., Barry S.C., Tsykin A., Farshid G., Vadas M.A., Khew-Goodall Y., Goodall G.J. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat. Cell Biol. 2008, 10:593-601.
39. Park S.M., Gaur A.B., Lengyel E., Peter M.E. The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev. 2008, 22:894-907.
40. Korpal M., Lee E.S., Hu G., Kang Y. The miR-200 family inhibits epithelial-mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEB1 and ZEB2. J. Biol. Chem. 2008, 283:14910-14914.
41. Tang S., Tao M., McCoy J.P., Zheng Z.M. Short-term induction and long-term suppression of HPV16 oncogene silencing by RNA interference in cervical cancer cells. Oncogene 2006, 25:2094-2104.
42. Wang X., Tang S., Le S.Y., Lu R., Rader J.S., Meyers C., Zheng Z.M. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PLoS One 2008, 3:e2557.
43. Li Y., Wang F., Xu J., Ye F., Shen Y., Zhou J., Lu W., Wan X., Ma D., Xie X. Progressive miRNA expression profiles in cervical carcinogenesis and identification of HPV related target genes for miR-29. J. Pathol. 2011, 224:484-495.
44. Wang X., Wang H.-K., McCoy J.P., Banerjee N.S., Rader J.S., Broker T.R., Meyers C., Chow L.T., Zheng Z.M. Oncogenic HPV infection interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E6. RNA 2009, 15:637-647.
45. Li B., Hu Y., Ye F., Li Y., Lv W., Xie X. Reduced miR-34a expression in normal cervical tissues and cervical lesions with high-risk human papillomavirus infection. Int. J. Gynecol. Cancer 2010, 20:597-604.
46. Witten D., Tibshirani R., Gu S.G., Fire A., Lui W.O. Ultra-high throughput sequencing-based small RNA discovery and discrete statistical biomarker analysis in a collection of cervical tumours and matched controls. BMC Biol. 2010, 8:58.
47. Q. Rao, H. Zhou, Y. Peng, J. Li, Z. Lin. Aberrant microRNA expression in human cervical carcinomas, Med.Oncol., (in press).
48. Pereira P.M., Marques J.P., Soares A.R., Carreto L., Santos M.A. MicroRNA expression variability in human cervical tissues. PLoS One 2010, 5:e11780.
49. Lee J.W., Choi C.H., Choi J.J., Park Y.A., Kim S.J., Hwang S.Y., Kim W.Y., Kim T.J., Lee J.H., Kim B.G., Bae D.S. Altered microRNA expression in cervical carcinomas. Clin. Cancer Res. 2008, 14:2535-2542.
50. Hu X., Schwarz J.K., Lewis J.S., Huettner P.C., Rader J.S., Deasy J.O., Grigsby P.W., Wang X. A microRNA expression signature for cervical cancer prognosis. Cancer Res. 2010, 70:1441-1448.
51. Lui W.O., Pourmand N., Patterson B.K., Fire A. Patterns of known and novel small RNAs in human cervical cancer. Cancer Res. 2007, 67:6031-6043.
52. Michael M.Z., O' Connor S.M., Holst Pellekaan N.G., Young G.P., James R.J. Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol. Cancer Res. 2003, 1:882-891.
53. Akao Y., Nakagawa Y., Kitade Y., Kinoshita T., Naoe T. Downregulation of microRNAs-143 and -145 in B-cell malignancies. Cancer Sci. 2007, 98:1914-1920.
54. Kent O.A., Chivukula R.R., Mullendore M., Wentzel E.A., Feldmann G., Lee K.H., Liu S., Leach S.D., Maitra A., Mendell J.T. Repression of the miR-143/145 cluster by oncogenic Ras initiates a tumor-promoting feed-forward pathway. Genes Dev. 2010, 24:2754-2759.
55. Nomine Y., Masson M., Charbonnier S., Zanier K., Ristriani T., Deryckere F., Sibler A.P., Desplancq D., Atkinson R.A., Weiss E., Orfanoudakis G., Kieffer B., Trave G. Structural and functional analysis of E6 oncoprotein: insights in the molecular pathways of human papillomavirus-mediated pathogenesis. Mol. Cell 2006, 21:665-678.
56. Ristriani T., Fournane S., Orfanoudakis G., Trave G., Masson M. A single-codon mutation converts HPV16 E6 oncoprotein into a potential tumor suppressor, which induces p53-dependent senescence of HPV-positive HeLa cervical cancer cells. Oncogene 2009, 28:762-772.
57. Green D.R., Kroemer G. Cytoplasmic functions of the tumour suppressor p53. Nature 2009, 458:1127-1130.
58. Riley T., Sontag E., Chen P., Levine A. Transcriptional control of human p53-regulated genes. Nat. Rev. Mol. Cell Biol. 2008, 9:402-412.
59. He L., He X., Lim L.P., de Stanchina E., Xuan Z., Liang Y., Xue W., Zender L., Magnus J., Ridzon D., Jackson A.L., Linsley P.S., Chen C., Lowe S.W., Cleary M.A., Hannon G.J. A microRNA component of the p53 tumour suppressor network. Nature 2007, 447:1130-1134.
60. Chang T.C., Wentzel E.A., Kent O.A., Ramachandran K., Mullendore M., Lee K.H., Feldmann G., Yamakuchi M., Ferlito M., Lowenstein C.J., Arking D.E., Beer M.A., Maitra A., Mendell J.T. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell 2007, 26:745-752.
61. Raver-Shapira N., Marciano E., Meiri E., Spector Y., Rosenfeld N., Moskovits N., Bentwich Z., Oren M. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol. Cell 2007, 26:731-743.
62. Yamakuchi M., Ferlito M., Lowenstein C.J. miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:13421-13426.
63. Sun F., Fu H., Liu Q., Tie Y., Zhu J., Xing R., Sun Z., Zheng X. Downregulation of CCND1 and CDK6 by miR-34a induces cell cycle arrest. FEBS Lett. 2008, 582:1564-1568.
64. Bommer G.T., Gerin I., Feng Y., Kaczorowski A.J., Kuick R., Love R.E., Zhai Y., Giordano T.J., Qin Z.S., Moore B.B., MacDougald O.A., Cho K.R., Fearon E.R. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr. Biol. 2007, 17:1298-1307.
65. Wang X., Meyers C., Guo M., Zheng Z.M. Up-regulation of p18Ink4c expression by oncogenic HPV E6 via p53-miR-34a pathway. Int. J. Cancer 2011, 129:1362-1372.
66. Christoffersen N.R., Shalgi R., Frankel L.B., Leucci E., Lees M., Klausen M., Pilpel Y., Nielsen F.C., Oren M., Lund A.H. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death. Differ. 2010, 17:236-245.
67. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., Knyazev P., Diebold J., Hermeking H. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
68. Martinez I., Gardiner A.S., Board K.F., Monzon F.A., Edwards R.P., Khan S.A. Human papillomavirus type 16 reduces the expression of microRNA-218 in cervical carcinoma cells. Oncogene 2008, 27:2575-2582.
69. Turner M.A., Palefsky J.M. Urokinase plasminogen activator expression by primary and HPV 16-transformed keratinocytes. Clin. Exp. Metastasis 1995, 13:260-268.
70. Riethdorf L., Riethdorf S., Petersen S., Bauer M., Herbst H., Janicke F., Loning T. Urokinase gene expression indicates early invasive growth in squamous cell lesions of the uterine cervix. J. Pathol. 1999, 189:245-250.
71. Au Yeung C.L., Tsang T.Y., Yau P.L., Kwok T.T. Human papillomavirus type 16 E6 induces cervical cancer cell migration through the p53/microRNA-23b/urokinase-type plasminogen activator pathway. Oncogene 2011, 30:2401-2410.
72. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D'Urso L., Pagliuca A., Biffoni M., Labbaye C., Bartucci M., Muto G., Peschle C., De Maria R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14:1271-1277.
73. Bandi N., Zbinden S., Gugger M., Arnold M., Kocher V., Hasan L., Kappeler A., Brunner T., Vassella E. miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res. 2009, 69:5553-5559.
74. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:13944-13949.
75. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:15524-15529.
76. Lerner M., Harada M., Loven J., Castro J., Davis Z., Oscier D., Henriksson M., Sangfelt O., Grander D., Corcoran M.M. DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp. Cell Res. 2009, 315:2941-2952.
77. Klein U., Lia M., Crespo M., Siegel R., Shen Q., Mo T., Ambesi-Impiombato A., Califano A., Migliazza A., Bhagat G., Dalla-Favera R. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell 2010, 17:28-40.
78. Aqeilan R.I., Calin G.A., Croce C.M. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2010, 17:215-220.
79. Zhao H., Kalota A., Jin S., Gewirtz A.M. The c-myb proto-oncogene and microRNA-15a comprise an active autoregulatory feedback loop in human hematopoietic cells. Blood 2009, 113:505-516.
80. Yin K.J., Deng Z., Hamblin M., Xiang Y., Huang H., Zhang J., Jiang X., Wang Y., Chen Y.E. Peroxisome proliferator-activated receptor delta regulation of miR-15a in ischemia-induced cerebral vascular endothelial injury. J. Neurosci. 2010, 30:6398-6408.
81. Sala A., Nicolaides N.C., Engelhard A., Bellon T., Lawe D.C., Arnold A., Grana X., Giordano A., Calabretta B. Correlation between E2F-1 requirement in the S phase and E2F-1 transactivation of cell cycle-related genes in human cells. Cancer Res. 1994, 54:1402-1406.
82. Campanero M.R., Armstrong M., Flemington E. Distinct cellular factors regulate the c-myb promoter through its E2F element. Mol. Cell. Biol. 1999, 19:8442-8450.
83. Sahin F., Sladek T.L. E2F-1 has dual roles depending on the cell cycle. Int. J. Biol. Sci. 2010, 6:116-128.
84. Melar-New M., Laimins L.A. Human papillomaviruses modulate expression of microRNA 203 upon epithelial differentiation to control levels of p63 proteins. J. Virol. 2010, 84:5212-5221.
85. Yi R., Poy M.N., Stoffel M., Fuchs E. A skin microRNA promotes differentiation by repressing 'stemness'. Nature 2008, 452:225-229.
86. Lena A.M., Shalom-Feuerstein R., Rivetti d., Aberdam V.D., Knight R.A., Melino G., Candi E. miR-203 represses 'stemness' by repressing DeltaNp63. Cell Death Differ. 2008, 15:1187-1195.
87. Truong A.B., Kretz M., Ridky T.W., Kimmel R., Khavari P.A. p63 regulates proliferation and differentiation of developmentally mature keratinocytes. Genes Dev. 2006, 20:3185-3197.
88. Grassmann R., Jeang K.T. The roles of microRNAs in mammalian virus infection. Biochim. Biophys. Acta 2008, 1779:706-711.
89. Nuovo G.J., Wu X., Volinia S., Yan F., Di Leva G., Chin N., Nicol A.F., Jiang J., Otterson G., Schmittgen T.D., Croce C. Strong inverse correlation between microRNA-125b and human papillomavirus DNA in productive infection. Diagn. Mol. Pathol. 2010, 19:135-143.
90. Scotto L., Narayan G., Nandula S.V., Subramaniyam S., Kaufmann A.M., Wright J.D., Pothuri B., Mansukhani M., Schneider A., Arias-Pulido H., Murty V.V. Integrative genomics analysis of chromosome 5p gain in cervical cancer reveals target over-expressed genes, including Drosha. Mol. Cancer 2008, 7:58.
91. Muralidhar B., Goldstein L.D., Ng G., Winder D.M., Palmer R.D., Gooding E.L., Barbosa-Morais N.L., Mukherjee G., Thorne N.P., Roberts I., Pett M.R., Coleman N. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J. Pathol. 2007, 212:368-377.
92. Cai X., Li G., Laimins L.A., Cullen B.R. Human papillomavirus genotype 31 does not express detectable microRNA levels during latent or productive virus replication. J. Virol. 2006, 80:10890-10893.
93. Zheng Z.M. Viral oncogenes, noncoding RNAs, and RNA splicing in human tumor viruses. Int. J. Biol. Sci. 2010, 6:730-755.
94. Narisawa-Saito M., Kiyono T. Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: roles of E6 and E7 proteins. Cancer Sci. 2007, 98:1505-1511.
95. McLaughlin-Drubin M.E., Munger K. The human papillomavirus E7 oncoprotein. Virology 2009, 384:335-344.
96. Yang C.H., Yue J., Fan M., Pfeffer L.M. IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis. Cancer Res. 2010, 70:8108-8116.
97. Iliopoulos D., Jaeger S.A., Hirsch H.A., Bulyk M.L., Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking inflammation to cancer. Mol. Cell 2010, 39:493-506.
98. Yang S.F., Yuan S.S., Yeh Y.T., Wu M.T., Su J.H., Hung S.C., Chai C.Y. The role of p-STAT3 (ser727) revealed by its association with Ki-67 in cervical intraepithelial neoplasia. Gynecol. Oncol. 2005, 98:446-452.
99. Sobti R.C., Singh N., Hussain S., Suri V., Bharti A.C., Das B.C. Overexpression of STAT3 in HPV-mediated cervical cancer in a north Indian population. Mol. Cell. Biochem. 2009, 330:193-199.
100. Shukla S., Shishodia G., Mahata S., Hedau S., Pandey A., Bhambhani S., Batra S., Basir S.F., Das B.C., Bharti A.C. Aberrant expression and constitutive activation of STAT3 in cervical carcinogenesis: implications in high-risk human papillomavirus infection. Mol. Cancer 2010, 9:282.
101. Nees M., Geoghegan J.M., Hyman T., Frank S., Miller L., Woodworth C.D. Papillomavirus type 16 oncogenes downregulate expression of interferon-responsive genes and upregulate proliferation-associated and NF-kappaB-responsive genes in cervical keratinocytes. J. Virol. 2001, 75:4283-4296.
102. Hatley M.E., Patrick D.M., Garcia M.R., Richardson J.A., Bassel-Duby R., van Rooij E., Olson E.N. Modulation of K-Ras-dependent lung tumorigenesis by microRNA-21. Cancer Cell 2010, 18:282-293.
103. Matlashewski G., Schneider J., Banks L., Jones N., Murray A., Crawford L. Human papillomavirus type 16 DNA cooperates with activated ras in transforming primary cells. EMBO J. 1987, 6:1741-1746.
104. Phelps W.C., Yee C.L., Munger K., Howley P.M. The human papillomavirus type 16 E7 gene encodes transactivation and transformation functions similar to those of adenovirus E1A. Cell 1988, 53:539-547.
105. Middleton K., Peh W., Southern S., Griffin H., Sotlar K., Nakahara T., El Sherif A., Morris L., Seth R., Hibma M., Jenkins D., Lambert P., Coleman N., Doorbar J. Organization of human papillomavirus productive cycle during neoplastic progression provides a basis for selection of diagnostic markers. J. Virol. 2003, 77:10186-10201.
106. Shai A., Brake T., Somoza C., Lambert P.F. The human papillomavirus E6 oncogene dysregulates the cell cycle and contributes to cervical carcinogenesis through two independent activities. Cancer Res. 2007, 67:1626-1635.
107. Yeung M.L., Yasunaga J., Bennasser Y., Dusetti N., Harris D., Ahmad N., Matsuoka M., Jeang K.T. Roles for microRNAs, miR-93 and miR-130b, and tumor protein 53-induced nuclear protein 1 tumor suppressor in cell growth dysregulation by human T-cell lymphotrophic virus 1. Cancer Res. 2008, 68:8976-8985.
108. Lee Y., Kim M., Han J., Yeom K.H., Lee S., Baek S.H., Kim V.N. MicroRNA genes are transcribed by RNA polymerase II. EMBO J. 2004, 23:4051-4060.
109. Lujambio A., Portela A., Liz J., Melo S.A., Rossi S., Spizzo R., Croce C.M., Calin G.A., Esteller M. CpG island hypermethylation-associated silencing of non-coding RNAs transcribed from ultraconserved regions in human cancer. Oncogene 2010, 29:6390-6401.
110. Bandres E., Agirre X., Bitarte N., Ramirez N., Zarate R., Roman-Gomez J., Prosper F., Garcia-Foncillas J. Epigenetic regulation of microRNA expression in colorectal cancer. Int. J. Cancer 2009, 125:2737-2743.
111. Saito Y., Liang G., Egger G., Friedman J.M., Chuang J.C., Coetzee G.A., Jones P.A. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006, 9:435-443.
112. Badal V., Chuang L.S., Tan E.H., Badal S., Villa L.L., Wheeler C.M., Li B.F., Bernard H.U. CpG methylation of human papillomavirus type 16 DNA in cervical cancer cell lines and in clinical specimens: genomic hypomethylation correlates with carcinogenic progression. J. Virol. 2003, 77:6227-6234.
113. Wentzensen N., Sherman M.E., Schiffman M., Wang S.S. Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science. Gynecol. Oncol. 2009, 112:293-299.
114. Huang T.H., Lai H.C., Liu H.W., Lin C.J., Wang K.H., Ding D.C., Chu T.Y. Quantitative analysis of methylation status of the PAX1 gene for detection of cervical cancer. Int. J. Gynecol. Cancer 2010, 20:513-519.
115. Wilting S.M., van Boerdonk R.A., Henken F.E., Meijer C.J., Diosdado B., Meijer G.A., le Sage C., Agami R., Snijders P.J., Steenbergen R.D. Methylation-mediated silencing and tumour suppressive function of hsa-miR-124 in cervical cancer. Mol. Cancer 2010, 9:167.
116. Git A., Dvinge H., Salmon-Divon M., Osborne M., Kutter C., Hadfield J., Bertone P., Caldas C. Systematic comparison of microarray profiling, real-time PCR, and next-generation sequencing technologies for measuring differential microRNA expression. RNA 2010, 16:991-1006.
117. Sato F., Tsuchiya S., Terasawa K., sujimoto G.T. Intra-platform repeatability and inter-platform comparability of microRNA microarray technology. PLoS One 2009, 4:e5540.
118. Dreher A., Rossing M., Kaczkowski B., Nielsen F.C., Norrild B. Differential expression of cellular microRNAs in HPV-11 transfected cells. An analysis by three different array platforms and qRT-PCR. Biochem. Biophys. Res. Commun. 2010, 403:357-362.
119. Ambros V., Bartel B., Bartel D.P., Burge C.B., Carrington J.C., Chen X., Dreyfuss G., Eddy S.R., Griffiths-Jones S., Marshall M., Matzke M., Ruvkun G., Tuschl T. A uniform system for microRNA annotation. RNA 2003, 9:277-279.
120. Friedman J.M., Jones P.A. MicroRNAs: critical mediators of differentiation, development and disease. Swiss. Med. Wkly. 2009, 139:466-472.
121. Guo M., Gong Y., Deavers M., Silva E.G., Jan Y.J., Cogdell D.E., Luthra R., Lin E., Lai H.C., Zhang W., Sneige N. Evaluation of a commercialized in situ hybridization assay for detecting human papillomavirus DNA in tissue specimens from patients with cervical intraepithelial neoplasia and cervical carcinoma. J. Clin. Microbiol. 2008, 46:274-280.
122. Jia R., Liu X., Tao M., Kruhlak M., Guo M., Meyers C., Baker C.C., Zheng Z.M. Control of the papillomavirus early-to-late switch by differentially expressed SRp20. J. Virol. 2009, 83:167-180.
123. Tang S., Tao M., McCoy J.P., Zheng Z.M. The E7 oncoprotein is translated from spliced E6*I transcripts in high-risk human papillomavirus type 16- or type 18-positive cervical cancer cell lines via translation reinitiation. J. Virol. 2006, 80:4249-4263.